Literature DB >> 17425912

Mucosal exposure to antigen: cause or cure of type 1 diabetes?

Georgia Fousteri1, Matthias von Herrath, Damien Bresson.   

Abstract

The human gut offers more than 200 m2 of mucosal surface, where direct interactions between the immune system and foreign antigens take place to eliminate pathogens or induce immune tolerance toward food antigens or normal gut flora. Therefore, mucosally administered antigens can induce tolerance under certain circumstances. In autoimmune diabetes, mucosal vaccination with autoantigens elicits some efficacy in restoring tolerance in mice, but it never succeeded in humans. Furthermore, in some instances autoimmunity can be precipitated upon oral or intranasal autoantigen administration. Therefore, it is difficult to predict the effect of mucosal vaccination on autoimmunity and much effort should be put into establishing better assays to reduce the risk for possible adverse events in humans and enable a rapid and smooth translation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17425912     DOI: 10.1007/s11892-007-0017-3

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   5.430


  67 in total

Review 1.  Design of immune-based interventions in autoimmunity and viral infections--the need for predictive models that integrate time, dose and classes of immune responses.

Authors:  M G von Herrath
Journal:  Novartis Found Symp       Date:  2001

Review 2.  Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells.

Authors:  H L Weiner
Journal:  Microbes Infect       Date:  2001-09       Impact factor: 2.700

3.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.

Authors:  B Bielekova; B Goodwin; N Richert; I Cortese; T Kondo; G Afshar; B Gran; J Eaton; J Antel; J A Frank; H F McFarland; R Martin
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

4.  Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells.

Authors:  C Ploix; I Bergerot; A Durand; C Czerkinsky; J Holmgren; C Thivolet
Journal:  Diabetes       Date:  1999-11       Impact factor: 9.461

5.  Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1.

Authors:  Jay M Sosenko; Jerry P Palmer; Carla J Greenbaum; Jeffrey Mahon; Catherine Cowie; Jeffrey P Krischer; H Peter Chase; Neil H White; Bruce Buckingham; Kevan C Herold; David Cuthbertson; Jay S Skyler
Journal:  Diabetes Care       Date:  2006-03       Impact factor: 19.112

6.  CD4+ but not CD8+ T cells are required for the induction of oral tolerance.

Authors:  P Garside; M Steel; F Y Liew; A M Mowat
Journal:  Int Immunol       Date:  1995-03       Impact factor: 4.823

7.  Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4.

Authors:  Shengwu Ma; Yan Huang; ZiQin Yin; Rima Menassa; James E Brandle; Anthony M Jevnikar
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-31       Impact factor: 11.205

8.  Tolerance induced by inhaled antigen involves CD4(+) T cells expressing membrane-bound TGF-beta and FOXP3.

Authors:  Marina Ostroukhova; Carole Seguin-Devaux; Timothy B Oriss; Barbara Dixon-McCarthy; Liyan Yang; Bill T Ameredes; Timothy E Corcoran; Anuradha Ray
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin.

Authors:  Z J Zhang; L Davidson; G Eisenbarth; H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

10.  Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23).

Authors:  D Daniel; D R Wegmann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

View more
  10 in total

1.  Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.

Authors:  Damien Bresson; Georgia Fousteri; Yulia Manenkova; Michael Croft; Matthias von Herrath
Journal:  J Autoimmun       Date:  2011-11-06       Impact factor: 7.094

Review 2.  Combination immunotherapies for type 1 diabetes mellitus.

Authors:  Paolo Pozzilli; Ernesto Maddaloni; Raffaella Buzzetti
Journal:  Nat Rev Endocrinol       Date:  2015-02-17       Impact factor: 43.330

3.  Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis.

Authors:  Georgia Fousteri; Amy Dave; Bret Morin; Shaida Omid; Michael Croft; Matthias G von Herrath
Journal:  J Autoimmun       Date:  2011-02-17       Impact factor: 7.094

Review 4.  Immunotherapy of type 1 diabetes: where are we and where should we be going?

Authors:  Xunrong Luo; Kevan C Herold; Stephen D Miller
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

5.  Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection.

Authors:  Georgia Fousteri; Jason R Chan; Yanan Zheng; Chan Whiting; Amy Dave; Damien Bresson; Michael Croft; Matthias von Herrath
Journal:  Diabetes       Date:  2010-09-23       Impact factor: 9.461

6.  Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma.

Authors:  G Fousteri; A Dave; A Bot; T Juntti; S Omid; M von Herrath
Journal:  Diabetologia       Date:  2010-05-20       Impact factor: 10.122

Review 7.  The pancreas in human type 1 diabetes.

Authors:  Patrick A Rowe; Martha L Campbell-Thompson; Desmond A Schatz; Mark A Atkinson
Journal:  Semin Immunopathol       Date:  2010-05-22       Impact factor: 9.623

8.  Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.

Authors:  Alusha A Mamchak; Yulia Manenkova; Wilhem Leconet; Yanan Zheng; Jason R Chan; Cynthia L Stokes; Lisl K M Shoda; Matthias von Herrath; Damien Bresson
Journal:  Diabetes       Date:  2012-02-23       Impact factor: 9.461

9.  Prevention or early cure of type 1 diabetes by intranasal administration of gliadin in NOD mice.

Authors:  David P Funda; Petra Fundova; Axel Kornerup Hansen; Karsten Buschard
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

Review 10.  Viral Infections and Autoimmune Disease: Roles of LCMV in Delineating Mechanisms of Immune Tolerance.

Authors:  Georgia Fousteri; Amy Dave Jhatakia
Journal:  Viruses       Date:  2019-09-21       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.